albuterol / budesonide vs Vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

albuterol / budesonide · Airsupra

Marketed by AstraZeneca

Approved in Asthmacombination (SABA + ICS)
Reliable signal

NCT03769090 · Phase 3 · completed

Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).

Next expected readout: February 2027 · NCT06422689 (registry estimate)

Reported efficacy

Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 (met)

Result source: NCT05505734

Vilanterol

Developed by GlaxoSmithKline

Phase 3 in Asthmasmall molecule
Partial signal

NCT00381667 · Phase 2 · completed

The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.

Reported efficacy

Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) (mixed)

Result source: NCT00600171

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalbuterol /​ budesonideVilanterol
Severe exacerbations, annualised rate0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
—Not reported
Trough FEV1, change0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
0.3 vs 0.1+0.1 vs placebo25 µg · wk 4 · n 99NCT00600171
8 other results
  • 0.3 vs 0.1 50 µg · wk 4 · n 100 · Phase 2 · primary NCT00600171
  • 0.3 vs 0.1 12.5 µg · wk 4 · n 97 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 6.25 µg · wk 4 · n 99 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 3 µg · wk 4 · n 98 · Phase 2 · primary NCT00600171
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767
ACQ-5, change—Not posted · NCT06502366—Not reported
OCS dose reduction—Not posted · NCT06502366—Not reported

Severe exacerbations, annualised rate

albuterol /​ budesonide
0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
Vilanterol
—Not reported

Trough FEV1, change

albuterol /​ budesonide
0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
Vilanterol
0.3 vs 0.1+0.1 vs placebo25 µg · wk 4 · n 99NCT00600171
8 other results
  • 0.3 vs 0.1 50 µg · wk 4 · n 100 · Phase 2 · primary NCT00600171
  • 0.3 vs 0.1 12.5 µg · wk 4 · n 97 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 6.25 µg · wk 4 · n 99 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 3 µg · wk 4 · n 98 · Phase 2 · primary NCT00600171
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767

ACQ-5, change

albuterol /​ budesonide
—Not posted · NCT06502366
Vilanterol
—Not reported

OCS dose reduction

albuterol /​ budesonide
—Not posted · NCT06502366
Vilanterol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. albuterol / budesonide: 4 of 4 rows · Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricalbuterol /​ budesonideVilanterol
Dropout rate
9.9%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
11.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
28.2%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
3.6%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
7.8%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
7.9%25 µgb
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
4.9%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
9.9%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
16.8%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12.2%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
21.1%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12.4%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.4%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.7%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
0.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
0.5%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0.5%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
1%25 µgb
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
0%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
1%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.9%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
0.9%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Serious AEs
5.2%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
3.8%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
3.1%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
2%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0%160/180
NCT06245551 · Phase 3
0%
NCT05555290 · Phase 3 · registry result, not featured evidence
0%
NCT04234464 · Phase 3 · registry result, not featured evidence
0%160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
0%25 µgb
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
0%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.9%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
—25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
0%100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
0%25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
160/180 μga
nasopharyngitis 7.5%
headache 4.3%
covid-19 3.3%
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
80/180 μg
nasopharyngitis 5.8%
headache 4.7%
covid-19 4.5%
NCT03769090 · Phase 3 · Asthma · phase 3
160/180 μg
upper respiratory tract infection 5.4%
covid-19 5.1%
nasopharyngitis 3.7%
NCT05505734 · Phase 3 · Asthma · phase 3
160/180 μg
nasopharyngitis 7.6% (placebo 5.5%)
headache 5.1% (placebo 7%)
dysphonia 2% (placebo 0%)
NCT03847896 · Phase 3 · Asthma · phase 3
80/180 μg
nasopharyngitis 6.4% (placebo 5.5%)
headache 4.9% (placebo 7%)
upper respiratory tract infection 1.5% (placebo 1%)
NCT03847896 · Phase 3 · Asthma · phase 3
160/180
bronchial irritation 1.6% (placebo 0%)
diarrhoea 0% (placebo 1.6%)
headache 0% (placebo 1.6%)
NCT06245551 · Phase 3
anxiety 1%
cough 1%
covid-19 1%
NCT05555290 · Phase 3 · registry result, not featured evidence
anxiety 0% (placebo 1.7%)
dyspnoea 0% (placebo 1.7%)
NCT04234464 · Phase 3 · registry result, not featured evidence
160/180 μg
miliaria 0%
NCT04848662 · Phase 1 · registry result, not featured evidence
25 µgb
headache 6.9% (placebo 7.8%)
upper respiratory tract infection 2% (placebo 2%)
nasopharyngitis 0% (placebo 3.9%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 13 more results
50 µg
headache 7.8% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 2% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12.5 µg
headache 9% (placebo 7.8%)
upper respiratory tract infection 3% (placebo 2%)
nasopharyngitis 0% (placebo 3.9%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
6.25 µg
headache 6.9% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 1% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
3 µg
headache 11.9% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 2% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
25 µg OD
headache 8.7% (placebo 4.3%)
nasopharyngitis 7.8% (placebo 10.3%)
oropharyngeal pain 5.2% (placebo 6%)
NCT01181895 · Phase 3 · registry result, not featured evidence
12.5 OD
nasopharyngitis 8.8% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
25 OD
nasopharyngitis 7.9% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
6.25 OD
nasopharyngitis 7% (placebo 7%)
headache 5.3% (placebo 3.5%)
influenza 3.5% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
100/25 µg AM
headache 25% (placebo 26.1%)
nasopharyngitis 12.5% (placebo 13%)
dysmenorrhoea 4.2% (placebo 0%)
NCT01287065 · Phase 2 · registry result, not featured evidence
100/25 µg PM
headache 32% (placebo 26.1%)
gastroenteritis 8% (placebo 0%)
nasopharyngitis 8% (placebo 13%)
NCT01287065 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 55.6% (placebo 40.7%)
nasopharyngitis 11.1% (placebo 7.4%)
oropharyngeal pain 11.1% (placebo 7.4%)
NCT01128595 · Phase 2 · registry result, not featured evidence
25 µg
upper respiratory tract infection 11.1% (placebo 0%)
headache 7.4% (placebo 7.7%)
pyrexia 7.4% (placebo 0%)
NCT01453296 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 9.8% (placebo 17.6%)
dysphonia 3.9% (placebo 0%)
mouth ulceration 3.9% (placebo 0%)
NCT01128569 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.
  2. bPopulation comparability has not been reviewed for 12 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

albuterol / budesonide

Severe Exacerbation 22.9% (n=1054) vs 26.2% (n=1014) AS MDI80/180 μg
event rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 241 Participants as posted
Severe Exacerbation Rate Annualized 0.49 vs 0.59 AS MDI per year80/180 μg
event rate · per year
NCT03769090 · Phase 3 · Asthma · phase 3
show 2 more results
0.15 vs 0.32 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
0.15 vs 0.33 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
ACQ-5 64.7% (n=1052) vs 62.1% (n=1014) AS MDI @ 24wk80/180 μg
responder rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 681 Participants as posted
Time to First Severe Exacerbation 5.1% (n=1209) vs 9.1% (n=1212) PT007160/180 μg
event count · % of participants
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 62 Participants as posted
show 3 more results
5.3% (n=1209) vs 9.4% (n=1212) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 64 Participants as posted
6% (n=1180) vs 10.7% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 71 Participants as posted
6.2% (n=1180) vs 11.2% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 73 Participants as posted
Total Systemic Glucocorticoid Exposure mg Per 23.2 vs 61.9 PT007 per year160/180 μg
absolute value · per year
NCT05505734 · Phase 3 · Asthma · phase 3
show 1 more result
23 vs 63 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
Total Systemic Glucocorticoid Duration 0.01 vs 0.03 PT007 months160/180 μg
absolute value · months
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
show 1 more result
0.01 vs 0.03 PT007 months*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
FEV1 AUC0-6 0.259 vs 0.097 placebo L @ 12wk160/180 μg
absolute change · L
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 258.6 mL as posted
show 1 more result
0.242 vs 0.097 placebo L @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 242.2 mL as posted
Time to FEV1 15 Increase 7.5 vs 14 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
7 vs 14 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
Duration of FEV1 15 Increase 185.5 vs 229.5 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
174 vs 229.5 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
ACQ-7 66.5% (n=161) vs 55.3% (n=159) placebo @ 12wk160/180 μg
responder rate · % of participants
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 107 Participants as posted
show 1 more result
65.5% (n=165) vs 55.3% (n=159) placebo @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 108 Participants as posted
FEV1 Max Fall 6.95% (n=64) vs 24.46% (n=64) placebo160/180
absolute value · percentage points
All subjects
NCT06245551 · Phase 3
FEV1 Max Fall LT 10 75% (n=64) vs 3.1% (n=64) placebo160/180
event count · % of participants
Maximum percentage fall <10%
NCT06245551 · Phase 3 · converted to % from 48 Participants as posted

+ 12 further endpoints in the CSV export.

Vilanterol

FEV1 AUC0-24 0.33 vs 0.137 placebo L @ 0.14wk25 µg
absolute change · L
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 9 more results
0.315 vs 0.149 placebo L @ 4wk25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.352 vs 0.137 placebo L @ 0.14wk50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.321 vs 0.149 placebo L @ 4wk50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.267 vs 0.137 placebo L @ 0.14wk12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.292 vs 0.149 placebo L @ 4wk12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.215 vs 0.137 placebo L @ 0.14wk6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.253 vs 0.149 placebo L @ 4wk6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.239 vs 0.137 placebo L @ 0.14wk3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.3 vs 0.149 placebo L @ 4wk3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Evening PEF 34 vs 0.4 placebo L/min25 µg
absolute change · L/min
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 5 more results
24.9 vs 11 placebo L/min @ 12wk25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
38.4 vs 0.4 placebo L/min50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
28.9 vs 0.4 placebo L/min12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
24.5 vs 0.4 placebo L/min6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
14 vs 0.4 placebo L/min3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Morning PEF 38.1 vs 1.9 placebo L/min25 µg
absolute change · L/min
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 5 more results
28 vs 14.2 placebo L/min @ 12wk25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
44 vs 1.9 placebo L/min50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
34.2 vs 1.9 placebo L/min12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
26.8 vs 1.9 placebo L/min6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
18.7 vs 1.9 placebo L/min3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Symptom-free 24 h Periods 36.4% (n=101) vs 14.2% (n=98) placebo25 µg
absolute change · percentage points
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more results
32.3% (n=102) vs 14.2% (n=98) placebo50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
26.8% (n=98) vs 14.2% (n=98) placebo12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
23.6% (n=101) vs 14.2% (n=98) placebo6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
22.6% (n=99) vs 14.2% (n=98) placebo3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Rescue-free 24 h Periods 43.4% (n=101) vs 15% (n=99) placebo25 µg
absolute change · percentage points
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more results
34% (n=102) vs 15% (n=99) placebo50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
29.6% (n=98) vs 15% (n=99) placebo12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
27.3% (n=101) vs 15% (n=99) placebo6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
25.8% (n=99) vs 15% (n=99) placebo3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
FEV1 Wm0 24 h 3.188 vs 2.811 placebo L @ 2wk100/25 µg AM
absolute change · L
NCT01287065 · Phase 2 · registry result, not featured evidence
show 2 more results
3.233 vs 2.811 placebo L @ 2wk100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
0.359 vs 0.289 placebo L @ 12wk25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
Rescue-free 24-h Period 21.7% (n=115) vs 14.6% (n=115) placebo @ 12wk25 µg OD
percent change · % of baseline
NCT01181895 · Phase 3 · registry result, not featured evidence
show 3 more results
2.98% (n=110) vs 14.4% (n=113) placebo @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
15.8% (n=112) vs 14.4% (n=113) placebo @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12.2% (n=113) vs 14.4% (n=113) placebo @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
Symptom-free 24-h Period 19.4% (n=115) vs 12.7% (n=115) placebo @ 12wk25 µg OD
percent change · % of baseline
NCT01181895 · Phase 3 · registry result, not featured evidence
show 3 more results
19.7% (n=110) vs 9.9% (n=113) placebo @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.3% (n=112) vs 9.9% (n=113) placebo @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
10.1% (n=113) vs 9.9% (n=113) placebo @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
FEV1 0.33 vs 0.301 placebo L @ 12wk25 µg OD
absolute change · L
24 hours, n= 95, 101, 100
NCT01181895 · Phase 3 · registry result, not featured evidence
Evening PEF Change L/Min 220.3 vs 215.9 placebo L/min @ 4wk25 µg OD
absolute change · L/min
NCT01573767 · Phase 2 · registry result, not featured evidence
show 5 more results
11.1 vs 5.9 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
222.4 vs 215.9 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.7 vs 5.9 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
221.4 vs 215.9 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
9.4 vs 5.9 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
Morning PEF Change L/Min 13.7 vs 6.4 placebo L/min @ 4wk25 µg OD
absolute change · L/min
NCT01573767 · Phase 2 · registry result, not featured evidence
show 5 more results
14.4 vs 7.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.9 vs 6.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
17 vs 7.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12 vs 6.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.3 vs 7.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
FEV1 Trough 3.191 vs 2.788 placebo L @ 2wk100/25 µg AM
absolute change · L
AM, n=22, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence
show 1 more result
3.285 vs 2.788 placebo L @ 2wk100/25 µg PM
AM, n=22, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · Vilanterol's landscape